Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
13
RNA Quote, Financials, Valuation and Earnings
Last price:
$31.84
Seasonality move
:
38.33%
Day range:
$30.85 - $32.63
52-week range:
$8.86 - $56.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
309.49x
P/B ratio:
2.53x
Volume:
2.8M
Avg. volume:
1.4M
1-year change:
278.81%
Market cap:
$3.8B
Revenue:
$9.6M
EPS (TTM):
-$2.89
Analysts' Opinion
-
Consensus RatingAvidity Biosciences has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $68.27, Avidity Biosciences has an estimated upside of 114.56% from its current price of $31.82.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $51.00 representing -60.28% downside risk from its current price of $31.82.
Fair Value
-
According to the consensus of 7 analysts, Avidity Biosciences has 114.56% upside to fair value with a price target of $68.27 per share.
RNA vs. S&P 500
-
Over the past 5 trading days, Avidity Biosciences has underperformed the S&P 500 by -0.08% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Avidity Biosciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Avidity Biosciences revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Avidity Biosciences reported revenues of $2.3M.
Earnings Growth
-
Avidity Biosciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Avidity Biosciences reported earnings per share of -$0.65.
Enterprise value:
2.2B
EV / Invested capital:
1.47x
Price / LTM sales:
309.49x
EV / EBIT:
--
EV / Revenue:
218.23x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-11.71x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-27.28%
Net Income Margin (TTM):
-2772.45%
Return On Equity:
-30.66%
Return On Invested Capital:
-30.66%
Operating Margin:
-4200.94%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $8.3M | $10.1M | $10.1M | $2.8M | $2.3M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$164.2M | -$222.1M | -$324.7M | -$58.6M | -$98.1M | |
| EBITDA | -$163M | -$220.2M | -$322M | -$58.1M | -$97.4M | |
| Diluted EPS | -$4.09 | -$2.99 | -$2.89 | -$0.71 | -$0.65 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $344.3M | $422M | $414.5M | $555.5M | $1.6B | |
| Total Assets | $346.1M | $425.9M | $430.5M | $573.2M | $1.6B | |
| Current Liabilities | $13.7M | $22.4M | $42.7M | $48.7M | $91.3M | |
| Total Liabilities | $26M | $31M | $53.6M | $55.7M | $137.4M | |
| Total Equity | $320.2M | $394.9M | $377M | $517.5M | $1.5B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$123.3M | -$174.8M | -$184.5M | -$36.8M | -$65.6M | |
| Cash From Investing | -$266.3M | -$188.9M | -$739M | -$31.5M | -$482.4M | |
| Cash From Financing | $123.2M | $305.6M | $1.2B | $40K | $342.5M | |
| Free Cash Flow | -$127M | -$179M | -$188.5M | -$37.7M | -$67.3M | |
RNA
Sector
Market Cap
$3.8B
$44.6M
Price % of 52-Week High
56.82%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
-20.92%
-0.68%
1-Year Price Total Return
278.81%
-29.09%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$32.70
200-day SMA
Sell
Level
$37.02
Bollinger Bands (100)
Sell
Level
38.89 - 47.21
Chaikin Money Flow
Sell
Level
-13.2M
20-day SMA
Sell
Level
$37.30
Relative Strength Index (RSI14)
Sell
Level
31.67
ADX Line
Buy
Level
9.34
Williams %R
Buy
Level
-84.6356
50-day SMA
Sell
Level
$42.36
MACD (12, 26)
Sell
Level
-3.35
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Neutral
Level
97.9M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.8885)
Sell
CA Score
(Annual)
Level (-0.5234)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (1.5846)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
Stock Forecast FAQ
In the current month, RNA has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The RNA average analyst price target in the past 3 months is $68.27.
-
Where Will Avidity Biosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Avidity Biosciences share price will rise to $68.27 per share over the next 12 months.
-
What Do Analysts Say About Avidity Biosciences?
Analysts are divided on their view about Avidity Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Avidity Biosciences is a Sell and believe this share price will drop from its current level to $51.00.
-
What Is Avidity Biosciences's Price Target?
The price target for Avidity Biosciences over the next 1-year time period is forecast to be $68.27 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is RNA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Avidity Biosciences is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RNA?
You can purchase shares of Avidity Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Avidity Biosciences shares.
-
What Is The Avidity Biosciences Share Price Today?
Avidity Biosciences was last trading at $31.84 per share. This represents the most recent stock quote for Avidity Biosciences. Yesterday, Avidity Biosciences closed at $31.82 per share.
-
How To Buy Avidity Biosciences Stock Online?
In order to purchase Avidity Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
